The abstract is read at the publisher; the summary is JClub's.
Epigenomic and three-dimensional chromatin remodeling in trastuzumab-resistant HER2+ breast cancer cells is linked to transcriptional reprogramming, with SGK1 showing increased promoter H3K4me3 and stronger chromatin interactions.
- Why it matters: Primary trastuzumab resistance limits treatment options for HER2-positive breast cancer, creating a need to identify the regulatory mechanisms that rewire gene expression.
- What they did: The study used integrative epigenomic and 3D genome analyses to compare resistant versus sensitive cells, focusing on promoter histone marks (H3K4me3, H3K27me3), enhancer activity, and promoter–enhancer interactions.
- The result: Resistant cells show widespread regulatory landscape changes, and SGK1 epigenetic activation suggests a framework for developing new therapeutic strategies targeting these chromatin features.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.